Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$9.47
+0.54 (+6.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $644.7M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.2B
P/E
63.1x
↑EV/EBITDA
10.7x
↓ROE
6.5%
↑Gross Margin
38.5%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.4%
FCF CAGR
+9.3%
FCF margin
3.0%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.58B · net income $349.9M · FCF $198.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.58B | $6.58B | $8.40B | $8.43B | $8.28B |
| Net Income | $349.9M | $349.9M | $648.1M | $540.7M | $383.2M |
| EBITDA | $716.7M | $716.7M | $1.16B | $1.02B | $726.8M |
| EPS | 0.46 | 0.46 | 0.86 | 0.71 | 0.51 |
| Gross Margin | 38.5% | 38.5% | 43.5% | 46.6% | 41.5% |
| Operating Margin | 5.7% | 5.7% | 11.7% | 10.6% | 7.4% |
| Net Margin | 5.3% | 5.3% | 7.7% | 6.4% | 4.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.16 | 0.14 | 0.23 |
| Current Ratio | 2.09 | 2.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $198.7M | $198.7M | $728.6M | $644.7M | $152.1M |
| Returns | |||||
| ROE | 6.5% | 6.5% | 12.3% | 8.2% | 7.7% |
| Valuation | |||||
| P/E | 63.13 | 63.13 | 18.17 | 29.37 | 32.10 |
| EV/EBITDA | 10.68 | 10.68 | 8.92 | 15.03 | 16.21 |
| P/B | 1.34 | 1.34 | 2.24 | 2.42 | 2.47 |
| Growth & Yield | |||||
| Revenue Growth | -21.7% | -21.7% | -0.3% | 1.8% | — |
| EPS Growth | -46.5% | -46.5% | 21.1% | 39.2% | — |
| Dividend Yield | 3.2% | 3.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
22.2%
EPS terminal req.
$0.84
Spread vs growth
-68.8%
5Y implied EPS CAGR
17.2%
EPS terminal req.
$1.02
Spread vs growth
-63.7%
10Y implied EPS CAGR
13.5%
EPS terminal req.
$1.64
Spread vs growth
-60.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.0%
Start / end P/E
18.1x → 20.6x
EPS bridge
0.86 → 0.46
Residual
-6.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.